Sign in Subscribe
Universities and colleges

Stabilization of Functionally Active CYP3A Uncovers New Insights into Clinically Relevant Drug Metabolism

Strategic Insights

— 1 min read

Researchers at the University of California, San Francisco have made a groundbreaking discovery in the field of drug metabolism, revealing that the stabilization of a functionally active CYP3A enzyme can influence clinically relevant drug metabolism. The study, published in the Journal of Biological Chemistry, demonstrates that the endoplasmic reticulum (ER)-anchored protein CYP3A is ubiquitinated in vivo by the E3 ubiquitin ligases gp78 and CHIP, leading to its degradation. However, when the researchers knocked down these ligases using RNAi, they found that the CYP3A enzyme was stabilized, resulting in increased levels of functionally active CYP3A, thereby challenging the previous notion that E3 recognition and subsequent ERAD of CYP3A proteins required ab initio their structural and/or functional inactivation.

Key Takeaways:

  • The study reveals that the CYP3A enzyme is ubiquitinated in vivo by the E3 ubiquitin ligases gp78 and CHIP, leading to its degradation.
  • Knockdown of these ligases using RNAi resulted in 80% knockdown of each hepatic Ub-ligase and a corresponding 2.5-fold CYP3A stabilization.
  • Stabilization of a functionally active CYP3A after RNAi knockdown of either of the E3s, coupled with the increased CYP3A4 loss on gp78 or CHIP coexpression, suggests that ERAD-associated E3 Ub-ligases can influence clinically relevant drug metabolism by effectively regulating the physiological CYP3A content and consequently its function.
  • The study provides new insights into the regulation of CYP3A enzyme activity and its potential impact on clinically relevant drug metabolism.

Statistics:

  • 50% of clinically relevant drugs are metabolized by the CYP3A4 enzyme (Kim et al., 2010).
  • 80% knockdown of each hepatic Ub-ligase resulted in a corresponding 2.5-fold CYP3A stabilization (Kim et al., 2010).
  • Coexpression of both CYP3A4 and gp78 in HepG2 cells resulted in enhanced CYP3A4 loss greater than that in corresponding cells expressing only CYP3A4 (Kim et al., 2010).

Sources:

  • Kim, S. M., et al. (2010). "Liver cytochrome P450 3A ubiquitination in vivo by gp78/autocrine motility factor receptor and C terminus of Hsp70-interacting protein (CHIP) E3 ubiquitin ligases: physiological and pharmacological relevance." Journal of Biological Chemistry, 285(46), 35866-77.
  • University of California, San Francisco, Department of Cellular & Molecular Pharmacology, Bioengineering & Therapeutic Sciences and the Liver Center.

Read more